

ONE HEALTH

“At Benno Tx, we have found ways to significantly increase survival rates of canine patients, without typical side effects of more traditional cancer treatments.”




Benn
o


Benno Therapeutics
is developing
the **iBoost technology** ,
a vaccine
targeting
the tumor vasculature
(**extracellular vimentin**)

IBOOST TECHNOLOGY

- Production of conjugate vaccine
- Engineering of vaccine protein containing truncated foreign antigen thioredoxin (TRXtr)




- Generation of less anti-TRXtr antibodies – generation of more anti-self-antigen antibodies (high titer, ~5% of all IgG, 0.5 mg/ml circulating IgG)



Huijbers et al, Vaccine, 2018

MECHANISM OF ACTION



Destruction of the tumor vasculature by the immune system



WHY TARGET THE TUMOR VASCULATURE?



1. Tackle resistance development

2. Prevent metastasis

PROOF OF CONCEPT

Phase 1/2 clinical study in 20 patient dogs with spontaneous **bladder** cancer

Ctrl = chemotherapy



- Excellent safety profile
- All dogs developed antibodies and showed clinical response
- Median overall survival: 374 vs 196 days in control group
- Inhibits metastasis
- Reduced resistance development

$p < 0.001$


Engbersen et al, Cancers, 2023

HIGH VALUE FOR ANIMAL ~~HEALTH~~




Clinical Perspective

- ✓ Safe **without side effects**
- ✓ Efficacious
- ✓ Inhibits Metastasis
- ✓ Prevents Resistance Development
- ✓ Easy IM administration □ GP



Commercial Perspective



INNOVATIVE MANUFACTURING APPROACH

Sustainable and low cost of goods



From seed to GMP < 1 year

INDUSTRY RECOGNITION



December 3 & 4, 2024
Lille, France



**ANIMAL HEALTH, NUTRITION
& TECHNOLOGY INNOVATION**
EUROPE

March 5 & 6, 2025
London, UK



THANK YOU!

